Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015

Journal of Neuro-Oncology

Volumn 62, Issue 3, 2003, Pages 251-258

  Bodell, William J ^a   Giannini, Donald D ^a   Singh, Saira ^b   Pietronigro, Dennis ^c   Levin, Victor A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OncoPharmaceuticals Inc   (United States)

^c Direct Therapeutics Inc   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCNU; Chemotherapy; DNA adducts; Drug delivery; Glioma

Indexed keywords

7 (2 HYDROXYETHYL)GUANINE; ALCOHOL; CARMUSTINE; DNA; DTI 015;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DNA ADDUCT; DNA ISOLATION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FIBROSARCOMA; MOUSE; NONHUMAN; SYSTEMIC THERAPY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; GLIOMA; GUANINE; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C3H; SKIN NEOPLASMS; SPECTROPHOTOMETRY, ULTRAVIOLET; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0038737173     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023383717833     Document Type: Article

References (35)

1. Wilson CB, Boldrey EB, Enot KJ: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemotherapy Res 54: 273-281, 1970
2. Mahaley MS Jr: Neuro-oncology index and review (adult primary brain tumors). J Neuro-Oncol 11: 85-147, 1991
3. Johnston TP, McCaleb GS, Montgomery JA: The synthesis of antineoplastic agents. XXXII. N-Nitrosoureas. Int J Med Chem 6: 669-681, 1963
4. Hyde KA, Acton E, Skinner WA, Greenberg J, Baker BR: Potential anticancer agents. LXII the relationship of chemical structure to antileukemic activity with analogs of 1-methyl-3-nitro-1-nitrosoguanidine (NSC-9369). II. J Med Pharm Chem 5: 1-14, 1962
5. Shapiro WR, Ausman JI, Rall DP: Studies on the chemotherapy of experimental; Brain tumors: Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea, cyclophosphamide, mithramycin and methotrexate. Cancer Res 30: 2401-2413, 1970
6. Barker M, Hoshino T, Gurcay O, Wilson CB, Nielsen SL, Downie R: Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 33: 976-986, 1973
7. Schold SC Jr, Rawlings III CE, Bigner SH, Bigner DD: Intracerebral growth of a human glioma tumor cell line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. Neurosurgery 12: 672-677, 1983
8. Schold SC Jr, Bigner DD: Treatment of five subcutaneous human glioma cell lines in athymic mice with carmustine, procarbazine and mitramycin. Cancer Treat Rep 67: 811-819, 1983
9. Gilman AG, Goodman LS, Rall TW, Murad TW (eds): Goodman and Gilman's the Pharmacological Basis of Therapeutics, 7th edn, pp. 1260-1261. Macmillan, New York, 1985
10. Perry JR, Brown MT, Gockerman JP: Acute leukemia following treatment of malignant glioma. J Neuro-Oncol 40: 39-46, 1998
11. Tomita T: Interstitial chemotherapy for brain tumors: Review. J Neuro-Oncol 10: 57-74, 1991
12. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 53: 329-333, 1993.
13. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers for recurrent gliomas. Lancet 345: 1008-1012, 1995
14. Pietronigro D, Drnovsky F, Cravioto H, Ransohoff J: Stereotactic intratumoral injection of DTI-015 in a rat intracranial T9 gliosarcoma model. Proc Am Asso Cancer Res 40: 583, 1999
15. Hassenbusch S, Levin V, Bodell W, Barnett G, Sawaya R, Pietronigro D: Stereotactic injection of DTI-015 into inoperable recurrent malignant gliomas: Phase I/II trial. J Neuro-Oncol 3(Suppl 1): S15, 2001
16. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM: Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 13: 671-682, 1996
17. Wang C-H, Li J, Teo CS, Lee T: The delivery of BCNU to brain tumors. J Control Rel 61: 21-41, 1999
18. Bodell WJ, Giannini DD, Hassenbusch S, Levin VA: Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. Neuro-Oncology 3: 241-245, 2001
19. Enam SA, Eisenberg AD, Norman D, Rosenblum ML: Patterns of spread and recurrence of glioma: Studies by neuroimaging. In: Mikkelson T, Bjerkvig MR, Laerum OD, Rosenblum ML (eds) Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations, pp. 133-159. Wiley-Liss Inc., New York, 1998
20. Naghipur A, Ikonomou MG, Kebarle P, Lown JW: Mechanism of action of (2-haloethyl)nitrosoureas on DNA: Discrimination between alternative pathways of DNA base modification by 1,3 bis(2-fluoroethyl)-1-nitrosourea by using specific deuterium labeling and identification of products by HPLC/Tandem mass spectrometry. J Am Chem Soc 112: 3178-3187, 1990
21. Ludlum DB: DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutation Res 233: 117-126, 1990
22. Bodell WJ, Tokuda K, Ludlum DB: Differences in DNA alkylation products formed in sensitive and resistant glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res 48: 4489-4492, 1988
23. Bodell WJ: Molecular dosimetry for sister chromatid exchange induction and cytotoxicity by monofunctional and bifunctional alkylating agents. Mutation Res 233: 203-210, 1990
24. Ye Q, Bodell WJ: Detection of N7-(2-hydroxyethyl) guanine adducts in DNA and 9L cells treated with 1-(2-chloroethyl)-1-nitrosourea. J Chromatogr B 694: 65-70, 1977
25. Bodell WJ: Effects of cations on the formation of DNA alkylation products in DNA reacted with 1-(2-chloroethyl)-1-nitrosourea. Chem Res Toxicol 12: 965-970, 1999
26. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF: A new mouse tumor model system (RIF-1) for comparison of endpoint studies. J Natl Cancer Inst 64: 595-604, 1980
27. Siemann DW: In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer 43: 367-377, 1981
28. Lelieveld P, Twentyman PR, Kallman RF, Brown JM: The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors VI. BCNU. Int J Radiation Oncol Biol Phys 5: 1549-1552, 1979
29. Lelieveld P, Scoles MA, Brown JM, Kallman RF: The effect of treatment in fractionated schedules with the combination of X-irradiated and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin. Int J Radiation Oncol Biol Phys 11: 111-121, 1985
30. Yapp DTT, Lloyd DK, Zhu J, Lehnert SM: Tumor treatment by sustained intratumoral release of cisplatin: Effects of drug alone and combined with radiation. Int J Radiation Oncol Biol Phys 39: 497-504, 1997
31. Doiron A, Yapp DTT, Olivares M, Zhu JXX, Lehnert S: Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res 59: 3677-3681, 1999
32. Levin VA: Clinical anticancer pharmacology: Some pharmacokinetic considerations. Cancer Treat Rev 13: 61-76, 1986
33. Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Sem Oncol 13: 70-82, 1986
34. Yoshii Y, Sugiyama K: Intercapillary distances in the proliferating area of human glioma. Cancer Res 48: 2938-2941, 1988
35. Blasberg RG, Patlak C, Fernstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculo-cisternal perfusion. J Pharmacol Exp Therapeutics 195; 73-83, 1975